Design and Development of Peptides from the Anti-Angiogenic Pigment Epithelial-Derived Factor for the Therapy of Prostate Cancer PRINCIPAL INVESTIGATOR:

Mirochnik Y, Filleur S, Volpert O. Pigment Epithelial derived factor: development of anti-angiogenic peptides. 2006. European J Cancer 4S (12):37 Presentation: Symposium on “Molecular Targets and Cancer Therapeutics”. Prague, Czech Republic 7-10 November 2006 Abstract: Mirochnik Y, Aurora A., Volpert O. Pigment epithelial derived factor: design and development of anti-angiogenic peptides for the therapy of prostate cancer. Mirochnik Y, Aurora A., Volpert O. Pigment epithelial derived factor: design and development of anti-angiogenic peptides for the therapy of prostate cancer. Presentation: IMPaCT Meeting. Atlanta, Georgia US Provisional Patent Application NU27084 “Me angiogenesis” Serial# 60/986,124, November 7, 2 CONCLUSIONS: We designed and tested sev epitope of PEDF, a protein with anti-angiogenic, r properties. One of the peptides (18-mer) demonstrated striking anti-angiogenic strongly inhibited prostate tumor growth in viv apoptosis in tumor and endothelial cells. Moreover, it was more effective then the parental r r ed PEDF receptor (6) in rder to generate small molecule non-protein PEDF mimetics. Such agents are more feasible point.